WuXi XDC and LigaChem Biosciences expands MoU to accelerate ADC development
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
The observations issued are neither repeated observations nor related to data integrity
USFDA inspection at Emcure Pharmaceuticals API facility
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Subscribe To Our Newsletter & Stay Updated